The first ‘tumour agnostic’ immunotherapy drug approval by the TGA will allow the pembrolizumab (Keytruda) to be used for a range of less common cancers characterised by biomarker signatures for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Pembrolizumab is already indicated for treatment of cancers including melanoma, non-small cell lung cancer and lymphoma. The ...
First pan-tumour approval goes to pembrolizumab
23 Jul 2019